BIO:ON Insight EN #17 · Sep 22, 2026 · Radiopharma Supply · Gene Therapy Approval · Antibody Screening

The edge in drugs is moving —
from what you discover to how you make it

Novartis's $1.2B radiopharma manufacturing deal, Ultragenyx's approval after a manufacturing rejection, and Roche's $1B push to screen 300,000 bispecifics. This week's three stories, read for your career.

Last issue we looked at grades of evidence. This week the lens moves from the drug itself to everything around it. Novartis put $1.2B behind a supply chain that races the clock, because radioactive isotopes decay. Ultragenyx got a gene therapy approved after a manufacturing problem had already blocked it once. And Roche committed up to $1B to screen more than 300,000 bispecific antibodies using automation. The edge is drifting from "what did you discover?" to "how do you make it, move it and find it?"

— Editor · MSc Biotechnology & Pharmaceutical Management

🔤 Word of the Week

CMC (Chemistry, Manufacturing and Controls)

The thread through Ultragenyx's approval (Story 2), and the backdrop to Stories 1 and 3

CMC is about how a drug is made and how its quality is guaranteed. Clinical trials prove "does this drug work?"; CMC proves "can you make it the same way, every time?" The FDA won't approve a drug on great clinical data alone if the facility, process or quality controls fall short. For gene therapies, cell therapies and radiopharmaceuticals, drugs that are alive or lose potency fast, CMC shapes approval and supply more than anywhere else.

💡 Analogy: A clinical trial is the tasting that proves "this recipe makes a great dish." CMC is the kitchen inspection that proves it comes out the same in any kitchen, every time. A brilliant dish still can't be sold if the kitchen fails. Radiopharma adds a twist: the dish spoils fast, so the kitchen has to be near the diner.

The trial win — "does it work?"

Efficacy (OS, response rate) and safety, proven in trials. It's what headlines lead with, but clearing it doesn't finish approval or supply.

CMC — "can we make it and protect it?"

Process consistency, facility standards (GMP), quality testing and the supply chain. Ultragenyx got stuck at exactly this gate and cleared it; Novartis is expanding it with $1.2B.

📰 This Week's Top 3 Stories

STORY 1 · RADIOPHARMA · SUPPLY CHAIN

Scaling Nuclear Medicine: Novartis Signs a $1.2B Manufacturing Deal to Strengthen Pluvicto Supply

Fierce Pharma · Novartis (NYSE: NVS) × Nucleus RadioPharma | Sep 18, 2026

Key Facts

Novartis signed an expanded $1.2 billion manufacturing and supply agreement with nuclear medicine specialist Nucleus RadioPharma to scale global production of Pluvicto, its targeted prostate cancer treatment. Pluvicto carries a radioactive isotope (lutetium-177) straight to cancer cells to destroy them from inside, and that isotope decays steadily, losing potency over time. So Novartis is moving money toward manufacturing closer to patients, ahead of pending Phase 3 readouts.

Plain-English Breakdown 🧩

A normal pill can sit in a warehouse and ship later. A radiopharmaceutical is more like fresh food with a very short shelf life: it has to reach the patient within days of being made (lutetium-177's half-life is about 6.7 days), and a late delivery can mean a patient misses that treatment cycle. In this field, who supplies fastest and closest matters as much as who makes the best drug.

🌍 Global Lens

Isotope supply is a global chokepoint: a small number of research reactors, many of them in Europe, produce the isotopes radiopharmaceuticals depend on. Because the finished product decays within days, manufacturing has to sit close to patients on each continent. That's why radiopharma investment is spreading across Europe, the US and Asia instead of concentrating in one hub.

Why it matters for your career: Radiopharma sits where GMP and radiation safety rules overlap, and it needs manufacturing and supply people who understand both, a niche that's growing fast.

📌 In nuclear oncology it's a race against the clock, and Novartis is buying speed and proximity. — Fierce Pharma summary

STORY 2 · GENE THERAPY · APPROVAL AFTER REJECTION

After a Manufacturing Rejection, FDA Approves Ultragenyx's Sanfilippo Gene Therapy at $3.95M

Fierce Biotech / BioSpace · Ultragenyx (NASDAQ: RARE) | Sep 17, 2026

Key Facts

Ultragenyx won FDA approval for Fayuvi (rebisufligene etisparvovec), the first gene therapy approved for Sanfilippo syndrome type A (MPS IIIA), a fatal childhood brain disorder in which waste builds up in brain cells and causes progressive childhood dementia. A single intravenous infusion delivers a working gene to brain cells. It was approved after an earlier FDA rejection over manufacturing concerns, and carries a $3.95 million wholesale price.

Plain-English Breakdown 🧩

A gene therapy is less a drug than a living process: the viral vector has to be made to the same purity and dose every time. Good clinical results weren't enough; if manufacturing quality (CMC) falls short, there's no approval. Ultragenyx was stopped at exactly that point, fixed the problem and got through. The next test is whether insurers and Medicaid can pay $3.95M.

🌍 Global Lens

The $3.95M price is set for the US, but health systems elsewhere usually pay much less for gene therapies or insist on outcome-based deals. Europe has already seen gene therapies withdrawn when companies and payers couldn't agree on a price. For ultra-rare cures, global access depends on the pricing model as much as the science.

Why it matters for your career: Approval hinged on manufacturing and access hinges on payers, two functions that rarely get the spotlight but decide whether patients actually get treated.

📌 A once-rejected gene therapy returns with its manufacturing fixed — now the $3.95M price tag is the test. — Fierce Biotech / BioSpace summary

STORY 3 · ANTIBODY DISCOVERY · PLATFORM DEAL

Searching 300,000 Combinations: Roche Commits up to $1B to Screen Next-Generation Autoimmune Antibodies

Fierce Biotech · Roche (SIX: ROG) × Dualitas Therapeutics | Sep 15, 2026

Key Facts

Roche partnered with biotech Dualitas Therapeutics in a deal worth up to $1 billion to run ultra-high-throughput screening of more than 300,000 new bispecific antibody candidates for severe autoimmune and inflammatory diseases. A bispecific binds two targets at once, but which design works best is hard to know without actually making and testing it. After the Hanmi obesity deal we covered in #14, Roche is now betting on automating and scaling discovery itself.

Plain-English Breakdown 🧩

Traditional discovery was closer to home cooking: a scientist makes dozens or hundreds of candidates and tests them one by one. Now it's becoming a factory-scale cook-off, where robots and data test hundreds of thousands of designs at once to pick the best. But winning the screen doesn't guarantee winning in the clinic. What Roche is buying is speed that improves the odds.

🌍 Global Lens

Deals like this show Big Pharma outsourcing early discovery to specialist platforms wherever they are. Automated, high-throughput labs are being built in the US, UK, Europe and China, and access to them is becoming a competitive edge in itself. The winners in discovery may be the ones with the fastest engines, not the most scientists.

Why it matters for your career: High-throughput discovery creates demand for people who combine lab skills with automation and data, a combination that's still relatively rare.

📌 Screening 300,000 candidates — speed and scale become the patent moat. — Fierce Biotech summary

🔬 This Week's Deep Dive

Deep Dive · The Edge Is in the Process

A supply chain racing decay, an approval decided by manufacturing, a screen of 300,000 candidates —
the edge is shifting to how drugs get made

① Discovering a drug is only the first step

Three corners of the industry, one story. Novartis spent $1.2B so a radiopharmaceutical reaches patients in time. Ultragenyx was approved only after fixing the manufacturing (CMC) problem that had blocked it. Roche committed up to $1B to automatically screen 300,000 candidates at the discovery stage. Discovery, manufacturing, supply: each stage of the process has become its own arena of competition.

② Three process arenas, three bottlenecks

Novartis × Nucleus	Ultragenyx	Roche × Dualitas
This Week's Signal
$1.2B manufacturing and supply deal	FDA approval · $3.95M price	Up to $1B · 300,000 candidates
The Bottleneck
Time — arrive before the isotope decays	Quality — earlier rejection over CMC	Speed — find the best candidate first
Key Risk
Spending before Phase 3 — demand risk	Will payers cover $3.95M?	A screen's winner isn't the clinic's

③ Why it matters — a great drug has to be makeable

However well a drug works in trials, if it can't be made, can't arrive in time, or the right candidate can't be picked, it never reaches patients. Ultragenyx showed the same drug can be blocked by one manufacturing issue, then approved once it's solved. Novartis is betting that supply is market share. Roche's screening sits at the other end: investing in the process of finding good candidates faster. The edge is moving from the age of discovery to the age of the process.

④ Career takeaway — learn to read manufacturing, supply and automation

✓ Skill to build

CMC, process development, QA/QC and supply chain are the functions most often named as the bottleneck in drug news right now. For new modalities like gene therapy, cell therapy and radiopharma, understanding manufacturing makes you rare. Add lab automation and data analysis and you can read both the discovery side and the manufacturing side, which is a genuinely valuable combination.

⚠ Trap

Seeing discovery R&D as the glamorous track and CMC as "support." Approval delays and supply problems frequently trace back to manufacturing, which makes CMC and supply chain front-line functions. Look only at discovery and you can miss where the demand and growth actually are.

💡 Editor's Insight

If there's one line for this week, it's this: the edge in new drugs is moving from discovery to the process. The radiopharma story stayed with me most. Even a great drug can make a patient miss a treatment cycle if it arrives a few days late, and that changes what "making a drug" really means. See you next issue. 🙏

📊 Numbers of the Week

$1.2B

Novartis's manufacturing and supply deal with Nucleus RadioPharma

An expanded agreement to scale Pluvicto's global production — money is flowing into a supply chain that races the clock.

$3.95M

Fayuvi's wholesale price (single dose)

The next test is how Medicaid programmes and private insurers pay for a one-time treatment for an ultra-rare disease.

300,000+

Bispecific candidates Roche and Dualitas will screen

Hundreds of thousands of two-in-one designs tested at speed to find the best — discovery is becoming a process too.

📈 3 Stocks That Moved This Week

Direction and catalyst, sketched — not exact prices. Check a real chart for that.

Ultragenyx Pharmaceutical

NASDAQ: RARE

▲ Sharp up

Shares jumped on Fayuvi's FDA approval, a turnaround for a programme once blocked over manufacturing and a proof point for ultra-rare gene therapy as a business. Hiring signal: a launch at this price usually means market access, medical affairs and commercial manufacturing/QA teams grow fast. (Directional sketch.)

Novartis

NYSE: NVS

— Flat

Shares barely moved on the $1.2B supply deal; it read as execution of an existing Pluvicto growth plan rather than a surprise. The real reaction will come with Phase 3 results. Hiring signal: expect radiopharma manufacturing and supply chain roles to grow. (Directional sketch.)

Regenxbio

NASDAQ: RGNX

▲ Up

Shares rose alongside Fayuvi's approval. Regenxbio's RGX-121 is on a clinical hold that blocks its refiling, and a peer clearing the FDA raised hopes that gene therapy hurdles do get solved. (Directional sketch.)

🔎 Why this pattern

This week, whether the manufacturing problem was solved decided the stock reaction: Ultragenyx cleared its gate and jumped, Regenxbio rose on the knock-on effect, and Novartis, whose deal was expected, stayed quiet. The market reacts strongly to newly confirmed information and calmly to execution it already expected. (All directional sketches — check a real chart for exact prices.)

🎯 Roles to Watch This Week

Teams worth watching based on this issue's news — not live job postings, so check each company's careers page for what's actually open.

Novartis / Nucleus RadioPharma — Radioligand Manufacturing & Supply Chain

Why now: a $1.2B expansion means scaling sites, isotope logistics and quality systems at the same time. Look under "Manufacturing," "Supply Chain" or "Technical Operations"; radiopharma CDMOs are worth watching too.

Ultragenyx — Gene Therapy CMC / Quality and Market Access

Why now: a newly approved $3.95M therapy needs commercial-scale quality and a payer strategy at once. Look under "Technical Operations / CMC," "Quality" and "Market Access."

Roche / Dualitas — Antibody Engineering / Automation & Data Science

Why now: screening 300,000 candidates needs people who bridge antibody engineering and data analysis. Look at Roche's discovery and biologics research postings.

🗓️ Dates to Watch

When / Event	Why It Matters
Q4 2026 – 2027 (expected) Ultragenyx — Fayuvi US launch and payer negotiations	Whether $3.95M turns into real access, and whether new models like outcomes-based deals appear.
H2 2026 – 2027 (expected) Novartis — follow-on Pluvicto Phase 3 data and new sites coming online	The $1.2B was spent ahead of the data, so Phase 3 results need to back up the demand forecast.
2027 (expected) Roche × Dualitas — first screening hits and preclinical entry	Which of the 300,000 candidates actually move forward is the platform's first report card.
Check exact dates before booking Manufacturing and discovery conference season — CPHI Worldwide, BIO-Europe, plus J.P. Morgan Healthcare in January	Relevant to this issue's CMC, supply and discovery themes; some offer discounted student passes, a cheap way to network into CMC, quality or discovery roles. Confirm each year's dates first.

Next time you read about a new drug, ask where and how it's made, and how it reaches the patient. You'll see straight away why CMC and supply chain roles are getting so much attention. See you in the next issue. 🙏

How was this issue?

👍 Loved it 🤔 Could be better

Found this useful? Share it with a classmate. 📤

Share the subscribe link

Follow along → @bio.on_insight

🔗 Sources

① Novartis bolsters radiopharma footprint with $1.2B manufacturing deal (Fierce Pharma, Sep 18, 2026) ② Ultragenyx wins FDA approval for Sanfilippo syndrome gene therapy (Fierce Biotech / BioSpace, Sep 17, 2026) ③ Roche bets up to $1B on Dualitas' screening platform for next-gen bispecifics (Fierce Biotech, Sep 15, 2026)

Global biotech & pharma news, translated into career signal —
every Tuesday, for students and early-career professionals.

🌐 Read on the web · past issues archive → bioon-website.vercel.app

The edge in drugs is moving —from what you discover to how you make it

The edge in drugs is moving —
from what you discover to how you make it